Merit Medical Systems, Inc.
(NASDAQ GS: MMSI)
Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Merit Medical Systems, Inc. ("Merit") on behalf of stockholders. A class action complaint has been filed against Merit, which alleges that defendants made false and misleading statements and/or failed to disclose adverse information regarding Merit’s business and prospects. Specifically, defendants allegedly failed to disclose that: (i) the integrations of Cianna and Vascular Insights, including their products, sales people, and R&D facilities, caused operational disruptions and reduced sales and were months behind schedule; (ii) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, particularly for Vascular Insights products which, as late as July 2019, had zero orders during fiscal 2019; and (iii) accordingly, Merit's reported financial guidance for fiscal years 2019 and 2020 was made without a reasonable basis. Therefore, Merit stock traded at artificially inflated prices of more than $62 per share.